Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma

Next Previous
X
Search
Trial Profile

An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belzutifan (Primary)
  • Indications Haemangioblastoma; Neuroendocrine tumours; Pancreatic cancer; Renal cell carcinoma; Von Hippel-Lindau disease
  • Focus Registrational; Therapeutic Use
  • Acronyms LITESPARK-004
  • Sponsors Merck Sharp & Dohme Corp.; Peloton Therapeutics

    • Most Recent Events

    • 22 Nov 2024 Results published in the Merck & Co Media Release.
    • 22 Nov 2024 According to a Merck & Co Media Release, the National Medical Products Administration (NMPA) in China has approved WELIREG (belzutifan), for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
    • 01 Nov 2024 Results assessing the efficacy of belzutifan in participants with von Hippel-Lindau disease-associated retinal hemangioblastomas published in the Ophthalmology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top